An evolving customer landscape, mounting pipeline and portfolio pressures, and intensifying competition are presenting new organizational and operational hurdles for Life Sciences companies. These complex market dynamics are requiring new levels of rigor and insight in business strategy development and problem-solving, both domestically and globally.
Deloitte’s Corporate Strategy services and solutions provide actionable insights that enable our Life Sciences clients to formulate near- and long-term strategies to address:
- The new portfolio: Generic drugs, devices from emerging market-based manufacturers, and other disruptive market entrants challenge traditional product-based portfolio strategies.
- M&A: Many Life Sciences companies are moving away from established, home-grown R&D models and adopting aggressive M&A and licensing strategies to quickly plug gaps left by patent expiry.
- Geographic mix: Emerging markets present new opportunities for revenue and lower-cost talent options.
- Innovation: Companies must redefine innovation within and around their core business to deliver differentiated value to their customers and develop new sources of revenue.